Tetrodotoxin, a Potential Drug for Neuropathic and Cancer Pain Relief?
| العنوان: | Tetrodotoxin, a Potential Drug for Neuropathic and Cancer Pain Relief? |
|---|---|
| المؤلفون: | M. Carmen Ruiz-Cantero, Carlos Gómez-Navas, Rafael González-Cano, Miguel Á. Tejada, Francisco R. Nieto, Miriam Santos-Caballero |
| المصدر: | Digibug. Repositorio Institucional de la Universidad de Granada instname Toxins Toxins, Vol 13, Iss 483, p 483 (2021) |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | 0301 basic medicine, cancer pain, Health, Toxicology and Mutagenesis, Analgesic, Neurotoxins, Sensory system, Review, Tetrodotoxin, Voltage-Gated Sodium Channels, Pharmacology, TTX, Toxicology, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Downregulation and upregulation, Ganglia, Spinal, Neoplasms, Medicine, Neurotoxin, Animals, Humans, Pain Management, neuropathic pain, Analgesics, business.industry, Sodium channel, musculoskeletal, neural, and ocular physiology, 030104 developmental biology, chemistry, nervous system, Pharmaceutical Preparations, Hyperalgesia, Neuropathic pain, Neuralgia, Cancer pain, business, 030217 neurology & neurosurgery, Sodium Channel Blockers |
| الوصف: | This publication was partially supported by grant CTS 109 from the Junta de Andalucia, grant INTRAIBS-2020-09 from Biosanitary Research Institute ibs.GRANADA, and grant PPJIA2020-06 from the University of Granada. Tetrodotoxin (TTX) is a potent neurotoxin found mainly in puffer fish and other marine and terrestrial animals. TTX blocks voltage-gated sodium channels (VGSCs) which are typically classified as TTX-sensitive or TTX-resistant channels. VGSCs play a key role in pain signaling and some TTX-sensitive VGSCs are highly expressed by adult primary sensory neurons. During pathological pain conditions, such as neuropathic pain, upregulation of some TTX-sensitive VGSCs, including the massive re-expression of the embryonic VGSC subtype NaV1.3 in adult primary sensory neurons, contribute to painful hypersensitization. In addition, people with loss-of-function mutations in the VGSC subtype NaV1.7 present congenital insensitive to pain. TTX displays a prominent analgesic effect in several models of neuropathic pain in rodents. According to this promising preclinical evidence, TTX is currently under clinical development for chemo-therapy-induced neuropathic pain and cancer-related pain. This review focuses primarily on the preclinical and clinical evidence that support a potential analgesic role for TTX in these pain states. In addition, we also analyze the main toxic effects that this neurotoxin produces when it is administered at therapeutic doses, and the therapeutic potential to alleviate neuropathic pain of other natural toxins that selectively block TTX-sensitive VGSCs. Junta de Andalucia CTS 109 Biosanitary Research Institute ibs.GRANADA INTRAIBS-2020-09 University of Granada PPJIA2020-06 |
| وصف الملف: | application/pdf |
| اللغة: | English |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::450febaf6ef3bd4425cc645c5b6f7964Test https://www.mdpi.com/2072-6651/13/7/483/pdf?version=1626583474Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....450febaf6ef3bd4425cc645c5b6f7964 |
| قاعدة البيانات: | OpenAIRE |
| الوصف غير متاح. |